Treating Vision, Not Signs: A Post-hoc Analysis Evaluating BCVA as an Early Indicator in Treat-and-Extend Management of DME
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Purpose
To determine whether significant changes in best-corrected visual acuity (BCVA) precede or coincide with increases in central retinal thickness (CRT) in diabetic macular edema (DME) during a treat-and-extend (T&E) regimen following initial edema resolution.
Methods
This post-hoc analysis included 60 eyes (60 participants) from the READ-3 clinical trial that achieved CRT <250 µm and were followed until edema recurrence. Following a six-month ranibizumab loading phase, patients were monitored through 24 months with as-needed retreatment. Significant changes were defined as ≥4 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and ≥30 µm on time-domain optical coherence tomography (TD-OCT). The temporal relationship between functional (BCVA) and anatomical (CRT) changes was analyzed.
Results
Median time to edema resolution was 10 months (IQR: 6-16) and to recurrence was 3 months (IQR: 2-3). 52 eyes (86.7%) had functional worsening and 43 (71.7%) had anatomical worsening. In 39 eyes exhibiting both types of deterioration, changes were concurrent in 24 (61.5%). Vision loss preceded anatomical recurrence (BCVA-led) in 23.1% of eyes, with a lead time of 1-4 months. Conversely, anatomical thickening preceded vision loss (OCT-led) in 15.4% of eyes, by a maximum of 2 months.
Conclusions
BCVA fluctuations frequently mirror CRT changes and can precede structural relapse, suggesting that BCVA is a sensitive indicator of DME activity. In resource-limited settings, BCVA may allow for earlier detection of recurrence than OCT alone.
Translational Relevance
Functional vision loss can precede structural edema recurrence, supporting the potential for home-based BCVA monitoring as a validated bridge for timely clinical intervention in DME.
